Radiomic MRI model to predict response to chemoradiotherapy in locally advanced cervical cancer
Official title: Developing a Radiomic MRI Model Predictive of Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer. A Prognostic, Retrospective, Open-label, Multicenter, Descriptive and Analytical Clinical Cohort Study
Run by Centre Hospitalier Universitaire de Nīmes · NCT07305727 · Data updated 2026-11-12
This project tests whether MRI-based radiomic features can predict how women with locally advanced cervical cancer will respond to combined chemotherapy and radiation.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Nîmes, Gard) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | August 1, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 7, 2026 |
| Trial ID | NCT07305727 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women with locally advanced cervical cancer who received definitive concomitant chemoradiotherapy and have pre- and post-treatment pelvic MRIs, available initial biopsy tissue, and at least two years of follow-up are the intended candidates.
✕Probably not a fit
Patients without usable MRI scans or initial biopsy specimens, those who received different treatment approaches, or those under legal guardianship are unlikely to benefit from this research.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will use the EPICOL clinical-biological cohort of patients treated with definitive concomitant chemoradiotherapy to develop a predictive model from radiomic features extracted from pelvic MRIs taken before and after treatment. The cohort includes 136 patients treated at Montpellier Cancer Institute and Nîmes University Hospital with at least two years of follow-up and available biopsy tissue. Imaging features will be correlated with outcomes such as recurrence-free survival and locoregional failure, and models will be trained and internally validated to identify patterns associated with poor or good response. The aim is to validate existing radiomic approaches and determine whether they can be applied in routine care.
Why it matters
Potential benefit: If successful, the model could identify patients unlikely to respond to standard chemoradiotherapy so clinicians can consider alternative or intensified treatments earlier.
How similar studies have gone: A few prior small studies have shown that radiomic MRI features may predict recurrence or survival in locally advanced cervical cancer, but those models need further exploration and validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated with exclusive radio-chemotherapy for locally advanced cervical cancer (stage Ib-IVb according to the FIGO classification). * Patients with a minimum of 2 years of post-treatment follow-up. * Patients for whom the initial biopsy specimen (prior to treatment) is available. * Patients who have not expressed their opposition to participating in the study. * Patients who are affiliated with or beneficiaries of a health insurance plan. Exclusion Criteria: * Patients under judicial protection, guardianship, or curatorship
Where it's running
-
Nimes University Hospital
Nîmes, Gard, France Recruiting
Study contacts
- Study coordinator: Frédéric FITENI, Professor
- Email: frederic.fiteni@chu-nimes.fr
- Phone: +334.34.03.46.69
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Enlonstobart with chemotherapy and radiotherapy for locally advanced cervical cancer
This study tests whether adding Enlonstobart to standard chemotherapy and chemoradiotherapy helps patients with locally advanced cervical cancer by increasing response rates and monitoring safety.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Immunotherapy Plus Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
This trial tests whether adding immunotherapy and chemotherapy to carbon ion radiotherapy can help women with locally advanced cervical cancer live longer without the cancer growing.
-
Dual PD1/CTLA4 immunotherapy with chemotherapy before surgery for locally advanced cervical cancer
This study tests a combo of a PD1/CTLA4 bispecific antibody with standard chemotherapy to see if it can improve outcomes before surgery in women with locally advanced cervical cancer.
-
Post-therapy stress symptoms after gynecologic brachytherapy in cervical cancer
This study tests whether patients undergoing uterovaginal brachytherapy for cervical cancer develop post-traumatic stress symptoms and how these symptoms change over up to 5 years.
-
Interactive video plus navigator to help Black women get cervical cancer screening
This project will test whether an interactive video paired with an in-person navigator helps Black women who are overdue get cervical cancer screening more often than a standard educational video.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.